<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01240161</url>
  </required_header>
  <id_info>
    <org_study_id>2008P000554</org_study_id>
    <nct_id>NCT01240161</nct_id>
  </id_info>
  <brief_title>Personalized Translational Platform for Biomarker Discovery in Brain Tumors</brief_title>
  <official_title>Personalized Translational Platform for Biomarker Discovery in Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marcelo F. Di Carli, MD, FACC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society of Nuclear Medicine and Molecular Imaging</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Electric</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The central hypothesis for this proposal is that multimodal (clinical, imaging, tissue)
      biomarkers will better predict early brain tumor response to treatments and will be more
      reliable prognostic markers in patients with malignant brain tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>7 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free Survival</measure>
    <time_frame>7 months</time_frame>
    <description>MRI and clinical criteria</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">37</enrollment>
  <condition>High Grade Glioma</condition>
  <arm_group>
    <arm_group_label>Patients with high grade gliomas</arm_group_label>
    <description>All subjects will have radiographically suspected or surgically proven de novo high grade gliomas. There are no control patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT</intervention_name>
    <description>Each patient will have 0-3 or more FLT-PET brain scans.</description>
    <arm_group_label>Patients with high grade gliomas</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presenting to BWH/DFCI emergency department (ED), inpatient, or neurology/
        neurosurgery/ radiation oncology clinics with newly diagnosed brain masses (suspected high
        grade gliomas) will be consented and enrolled in this study after adequate explanation of
        the risks and benefits of the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed or suspected high grade glioma ≥ 1cm in diameter on postoperative
             anatomic imaging (contrast MRI), prior to initiation of chemoXRT

          -  Anticipated survival ≥6 months

          -  Able to give informed consent

          -  Capable of undergoing MRI and PET scans without the need for sedation or general
             anesthesia

          -  Male or Female

        Exclusion Criteria:

          -  Prior radiation therapy and chemotherapy to the brain

          -  Active intracranial infection or nonglial brain mass.

          -  Recent large intracranial hemorrhage (&lt;1 month)

          -  Expected survival &lt;6 months

          -  Pregnant or nursing

          -  Renal failure

          -  Lives far from BWH and/or is unwilling/ unable to return for scheduled imaging visits.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie Kijewski, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California at San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2010</study_first_submitted>
  <study_first_submitted_qc>November 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2010</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Marcelo F. Di Carli, MD, FACC</investigator_full_name>
    <investigator_title>Chief of Nuclear Medicine/PET</investigator_title>
  </responsible_party>
  <keyword>Glioblastoma multiforme</keyword>
  <keyword>FLT</keyword>
  <keyword>PET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

